(7 September 2022, Milan, Italy) Vitamin D levels affect overall survival for melanoma (skin cancer) patients, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown.
2022
Metabolic Enzyme Inhibition Kills Melanoma Cells, Stops Tumor Growth
Researchers at Sanford Burnham Prebys have shown for the first time that inhibiting a key metabolic enzyme selectively kills melanoma cells and stops tumor growth.
Phase 1 Trial of Darovasertib Monotherapy Enrolls First Patient With Uveal Melanoma
A patient enrolled in the phase 1 NADOM trial of darovasertib alone in non-metastatic uveal melanoma shows early signs of clinical efficacy.
Sequential Treatment With Immunotherapy and Targeted Therapy Denotes OS Benefit in BRAF-Mutant Melanoma
Immunotherapy in the form of ipilimumab (Yervoy) plus nivolumab (Opdivo) followed by the targeted therapy combination encorafenib (Braftovi) plus binimetinib (Mektovi) elicited an overall survival (OS) benefit in patients with untreated BRAF-mutated metastatic melanoma, according to findings from the phase 2 SECOMBIT trial (NCT02631447).